

Overview of CML related sessions at 20th EHA Meeting in Vienna

Time slots	Sessions	Location
June 11th (Thursday)		
8.00 – 10.00	Satellite Symposium: When is ponatinib a suitable treatment option for patients with CP-CML and how can we optimize benefit/risk? Chairs: • Prof. Günther Gastl (Medizinische Universität Innsbruck, Austria) • Prof. Martin Müller (Universitätsklinikum Mannheim der Universität Heidelberg III, Germany) Program: • Chairman's welcome: M. Müller • CML patients resistant due to mutations: H. Hansen • CML patients failing nilotinib or dasatinib: F. Cervantes • CV monitoring and risk mitigation of TKI therapy: G. Rosti • Closing remarks: G. Gastl Supported by Ariad	Room C2

Time slots	Sessions	Location
10.45 – 12.45	Satellite Symposium: Optimizing patient outcomes in CML Chair: • Prof. Michele Baccarani (University of Bologna, Italy) Program: • Welcome: M. Baccarani • Perspective on frontline therapy selection in patients with CML-CP: G. Saglio • Importance of early response and considerations for treatment switch: B. Leiber • Patient cases & audience polling: M. Baccarani • Molecular monitoring best practices: S. Branford • Challenges for global standardization of BCR-ABL1 testing- panel discussion & audience questions: M. Baccarani • TFR current status & remaining questions: T. Hughes • Closing remarks: M. Baccarani Supported by Novartis	Room A7

Time slots	Sessions	Location
13.30 – 15.30	Satellite Symposium: The CML Journey: Long-term survival necessitates patient centricity Chair: • Prof. Andreas Petzer (Krankenhaus der Barmherzigen Schwestern, Linz, Austria) Program: • Welcome & introduction: A. Petzer • The CML journey: The case for patient centricity: P. la Rosée • Beginning the journey: Enabling success in CML: G. Rosti • Continuing the journey living with CML: J. Cortes • The Journey ahead: Aiming for cure in CML: T. Turhan Supported by Bristol-Myers Squibb	Room C2

Time slots	Sessions	Location
18.30 – 20.00	Satellite Symposium: Molecular monitoring in CML – from the bench to the bedside Chair: • Prof. Nick Cross (University of Southampton, Salisbury, UK) Program: • Chairman's welcome: N. Cross • The fundamentals of molecular monitoring: S. Branford • Defining a molecular response: N. Cross • ELN milestones: patient in warning at 3-mo: G. Rosti • Velocity at BCR-ABL decline vs. 10% milestone: S. Branford • Low levels of disease: S. Branford • Rising BCR-ABL levels – what's next?: T. Sacha • Discordant results at critical time-points: G. Rosti • Alternative BCR-ABL transcripts: N. Cross • Closing remarks: N. Cross Supported by Novartis	Room Strauss 1
June 12th (Friday)		
8.00 – 9.30	Education Session: Chronic Myeloid Leukemia Chair: • Prof. Andreas Hochhaus (Universität Jena, Germany) Program: • Biology of CML: D. Perrotti • Markers and targets of neoplastic stem cells in CML: P. Valent • New methodologies and monitoring tools for CML: S. Soverini	Room C2

Time slots	Sessions	Location
17.15 – 18.45	Satellite Symposium: Evolution of treatments in acute and chronic leukaemia Chair: - Prof. Jane Apperley (Hammersmith Hospital, London, UK) Program: - Welcome & Introduction: J. Apperley - Historical perspective in CML: Leading the way from targeted therapy to cure: J. Apperley - The coming of age of ALL: Novel therapeutic approach in ALL: S O'Brian - Translating biological markers into therapeutic advances in AML: R. Schlenk - Forty years of 7+3: How can we improve outcomes in AML?: S. Castaigne Supported by Pfizer	Room Strauss 2
June 14th (Saturday)		
8.00 – 9.30	Education Session: Chronic Myeloid Leukemia Chair: - Prof. Andreas Hochhaus (Universität Jena, Germany) Program: - Biology of CML: D. Perrotti - Markers and targets of neoplastic stem cells in CML: P. Valent - New methodologies and monitoring tools for CML: S. Soverini	Room C2

Time slots	Sessions	Location
9.45 – 10.45	Scientific Working Group: ELN-EHA-SWG on CML Chair: - Prof. Rüdiger Hehlmann (Medizinische Fakultät Mannheim der Universität Heidelberg, Germany) Program: - Standardization of deep molecular response: A. Hochhaus - Mechanism(s) of IFN alpha activity in CML: A. Burchert - Scope of BCR-ABL decline vs. absolute BCR-ABL level at 3 months: B. Hanfstein - Mechanisms of adverse TKI reactions: D. Rea	Room A8
14.30 – 15.30	Clinical debate: To stop or not to stop TKI in molecular remission of CML? Program: - No: Speaker Prof. Andreas Hochhaus - Yes: Speaker Prof. François-Xavier Mahon	Room A7